This study evaluates the efficacy and safety of intravenous reinduction or intravenous administration at regular intervals of ustekinumab. It consists of escalation treatment period (Week 0 to 52); and safety follow up visit (24 weeks after last dose). Study assessments will include Harvey-Bradshaw index (HBI), Physician Global Assessment Score (PGA), laboratory evaluations, endoscopic evaluation, review of concomitant medications and adverse events (AEs).
The primary purpose of this study is to evaluate the efficacy and safety of intravenous reinduction or intravenous administration at regular intervals of ustekinumab in participants with loss of response to standard regimen.